Viewing Study NCT03245957


Ignite Creation Date: 2025-12-24 @ 6:48 PM
Ignite Modification Date: 2025-12-25 @ 4:20 PM
Study NCT ID: NCT03245957
Status: UNKNOWN
Last Update Posted: 2019-03-07
First Post: 2017-08-08
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: HDL Dysfunction During the Acute Stage of Stroke
Sponsor: Centre Hospitalier Universitaire de la Réunion
Organization:

Study Overview

Official Title: HDL Dysfunction During the Acute Stage of Stroke
Status: UNKNOWN
Status Verified Date: 2019-03
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: RUSH
Brief Summary: The study investigates the effect of plasma myeloperoxidase (MPO) concentrations on HDL dysfunction during the acute stage of ischemic and haemorrhagic strokes.
Detailed Description: MRI or CT scan are used to confirm the diagnosis of haemorrhagic, ischemic and mimick stroke.

Plasma anf HDL-MPO concentrations, as well as potent HDL dysfunction, are compared in the 3 cases.

The investigators hypothesis is that MPO concentrations and subsequent HDL dysfunction could be higher in ischemic strokes than in haemorrhagic ones. MPO could be a examined as a potent marker of early stage of ischemic stroke.

Plasma MPO levels could also be discriminant regarding the mimick strokes in patient exhibiting stroke clinical picture.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: